Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gilca Nachtigal"'
Autor:
Gilca Nachtigal, Marco Antônio Schilling, Andréia Dias Almeida, Tito Vanelli Costa, Moema Nene, Erica Lammerhirt Ottoni, Marcelo Capra, Tânia Hellwig, Liane Esteves Daudt, Mayde Seadi Torriani, Laura Fogliatto, Mario Sérgio Fernandes, Mariza Shaan, Christina G S Fraga, Katia Fassina, Lucia Mariano da Rocha Silla, Adriana Zardo, Denise Almeida
Publikováno v:
Blood. 116:4487-4487
Abstract 4487 Background: Imatinib treatment for Chronic Myeloid Leukemia (CML) was first introduced in Brazil in 2001, initially used as second line therapy for patients resistant or intolerant to interferon (IFN). In 2008 imatinib was adopted as fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6764e77c733969bd19924c0b7fef044b
https://doi.org/10.1182/blood.v116.21.4487.4487
https://doi.org/10.1182/blood.v116.21.4487.4487
Autor:
Andréia Dias Almeida, Tito Vanelli Costa, Gilca Nachtigal, Katia Fassina, Adriana Zardo, Denise Almeida, Lucia Mariano da Rocha Silla, Liane Esteves Daudt, Mario Sérgio Fernandes, Christina G S Fraga, Marcelo Capra, Laura Fogliatto, Mariza Schaan, Moema Nene, Marco Antônio Schilling, Tânia Hellwig, Erica Lammerhirt Ottoni
Publikováno v:
Blood. 116:2300-2300
Abstract 2300 Introduction: Imatinib mesylate (Gleevec) treatment for Chronic Myelogenous Leukemia (CML) was first introduced in Brazil in 2003, initially used as second line therapy for patients resistant or intolerant to interferon. In 2004 imatini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6efab3bfc06b12c749d1e5ffa39e462b
https://doi.org/10.1182/blood.v116.21.2300.2300
https://doi.org/10.1182/blood.v116.21.2300.2300
Autor:
Marco Antônio Schilling, Adriana Wink, Ingrid Mito, Victor Hugo Lenz, Luciana Tagliari, Denise Pereira, Lisandra Dellacosta, Mariza Schaan, Adriana Zardo, Gilca Nachtigal, Waldir Veiga Pereira, Mario Sérgio Fernandes, Cheila Eickhof, Moema Nene, Tânia Hellwig, Virginia Maria Coser, Laura Fogliatto, Lucia Mariano da Rocha Silla, Dalnei Veiga Pereira, Aletea Zago, Marcelo Capra, Sabrina Wisenstein, Inez Guterrez, Roque Lorandi, Tito Vanelli
Publikováno v:
Blood. 112:4286-4286
CML is a well characterized disease with a known chromosomal abnormality. The inhibition of BCR-ABL protein tyrose kinase activity represented an advance in the treatment of this disease. Imatinib is effective in chronic, accelerated and blastic phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22a96fcf1af0992d997923d67cdcf708
https://doi.org/10.1182/blood.v112.11.4286.4286
https://doi.org/10.1182/blood.v112.11.4286.4286